Indication
Metastatic or Locally Advanced Solid Tumors
2 clinical trials
3 products
Clinical trial
A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of Y101D, a Recombinant Anti-PD-L1 and TGF-β Bispecific Antibody for Injection, in Patients With Metastatic or Locally Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-03-15
Product
Y101DProduct
Cohort 5 of Y101DClinical trial
PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMORStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Product
IMC-001